Researchers at Washington University have developed a universal blood test capable of detecting early brain damage years before Alzheimer’s disease symptoms appear. The diagnostic method measures a filamentous protein called Nfl that leaks from dying nerve cells into the cerebrospinal fluid and bloodstream.
University of Washington and German Institutions Publish Diagnostic Findings
Rather than targeting standard Alzheimer's markers like beta-amyloid, the universal blood test evaluates structural neuronal protein levels to assess overall brain injury.
NfL stands for neurofilament light chain, a structural component that forms part of the internal skeleton of neurons. When nerve cells sustain damage or die due to neurodegenerative processes, NfL escapes into the surrounding fluid and eventually crosses into the bloodstream, where it serves as a quantifiable gauge of ongoing cellular destruction.
Clinical Trials Track Preclinical Alzheimer’s Progression Across 400 Participants
Investigators tested the diagnostic approach on a cohort of more than 400 individuals. The participant group included 247 carriers of genetic mutations linked to rare forms of early-onset familial Alzheimer’s disease, alongside 162 healthy family members who served as a baseline control group.
Data from the trial showed that rising concentrations of the NfL protein in the blood closely mirrored the extent of underlying brain damage. Researchers confirmed that tracking these protein shifts over time allows clinicians to predict how the neurodegenerative process will evolve long before cognitive impairment manifests in patients.
Future Applications Beyond Familial Alzheimer’s Disease
While current trials focused specifically on patients with rare familial forms of early-onset Alzheimer’s disease, the research team aims to broaden the clinical utility of the assay. Investigators indicate that the universal nature of the blood test could eventually support the evaluation of diverse forms of brain injury and neurodegeneration.
The findings offer a concrete biomarker strategy for identifying preclinical pathology. By shifting the detection window years ahead of clinical onset, the blood-based assay establishes a measurable baseline for tracking disease trajectory and therapeutic interventions in neurology.
